John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

EditorialPublication Exclusive

Small molecules, ‘big data’ and the EMR

HemOnc Today, May 10, 2015
John Sweetenham, MD
It’s strange how apparently unrelated events sometimes seem to converge into a common theme. During the past couple weeks, I attended a preview of —…
EditorialPublication Exclusive

AICR report reveals new angle on ‘mismatch repair’ in cancer

HemOnc Today, March 10, 2015
John Sweetenham, MD
The World Health Organization designated Feb. 4 as World Cancer Day. I know this only because I happened to see it mentioned on Twitter. Otherwise, I…
EditorialPublication Exclusive

Déjà vu all over again — or am I missing the take-home message?

HemOnc Today, February 10, 2015
John Sweetenham, MD
In my clinic recently, I saw a vigorously healthy 79-year-old woman newly diagnosed with diffuse large B-cell lymphoma. She has virtually no…
EditorialPublication Exclusive

Robust data needed to settle maintenance therapy debate in hematologic malignancies

HemOnc Today, January 10, 2015
John Sweetenham, MD
The value of post-induction maintenance therapy in hematologic malignancies has gained renewed attention over the last few years. For the most part…
EditorialPublication Exclusive

A new angle on ‘patient experience’ in oncology: The challenge of patient-reported outcomes

HemOnc Today, December 10, 2014
John Sweetenham, MD
“Listen to your patient, he is telling you the diagnosis.”
— Sir William Osler
EditorialPublication Exclusive

Data-based medicine: When data and ‘opinion’ collide

HemOnc Today, November 25, 2014
John Sweetenham, MD
As a hematology/oncology fellow, I was fortunate enough to have a remarkable medical oncologist, Ben Mead, FRCR, FRCP, as a mentor. His approach to…
EditorialPublication Exclusive

Cancer progress reports: The gap between discovery and delivery

HemOnc Today, October 10, 2014
John Sweetenham, MD
In the past year or so, there have been several notable, “big-picture” reports about the state of cancer research, care and survival in…
EditorialPublication Exclusive

The changing face of our major meetings: Evolution or revolution?

HemOnc Today, September 10, 2014
John Sweetenham, MD, PhD
One morning in late July, I was poised over my laptop at exactly 9 a.m. Mountain time, ready for the ASH Annual Meeting and Exposition registration…
EditorialEditorial

From research funding to drug pricing: 12 questions to ask your political candidates

HemOnc Today, July 10, 2014
Derek Raghavan, MD, PhD; John Sweetenham, MD
This is the first edition of HemOnc Today with the two of us at the helm as chief medical editors, and we wish to signal the event by providing a…
Editorial

Response-adapted therapy of lymphoma: Real progress or really confusing?

HemOnc Today, August 10, 2014
John Sweetenham, MD
In the past few years, the lymphoma literature has featured an increasing number of studies — some well-designed, most not so — designed…